- Home
- CPRX
as of 03-10-2026 3:29pm EST
$24.87
+$0.08
+0.32%
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 3.0B | IPO Year: | 2006 |
| Target Price: | $35.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.68 | EPS Growth: | 28.24 |
| 52 Week Low/High: | $19.05 - $26.56 | Next Earning Date: | N/A |
| Revenue: | $119,072,803 | Revenue Growth: | 16.39% |
| Revenue Growth (this year): | 8% | Revenue Growth (next year): | 9.77% |
| P/E Ratio: | 14.38 | Index: | N/A |
| Free Cash Flow: | 208.6M | FCF Growth: | -12.81% |
Stock Insider Trading Activity of Catalyst Pharmaceuticals Inc. (CPRX)
Harper Molly
Sell
Director
CPRX Dec 12, 2025
Avg Cost/Share
$23.33
Shares
26,746
Total Value
$621,920.29
Owned After
13,579
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Harper Molly | CPRX | Director | Dec 12, 2025 | Sell | $23.33 | 26,746 | $621,920.29 | 13,579 |
Latest Catalyst Pharmaceuticals Inc. News
CPRX Breaking Stock News: Dive into CPRX Ticker-Specific Updates for Smart Investing
Zacks
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
📈
AI Sentiment
Highly Positive
9/10
Argus Research
CPRX: Lowering target price to $26.00
Compare CPRX vs Leading Stocks
See how CPRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CPRX Catalyst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.